Concomitant LATE-NC in Alzheimer's disease is not associated with increased tau or amyloid-β pathological burden

被引:16
|
作者
McAleese, K. E. [1 ]
Walker, L. [1 ]
Erskine, D. [1 ]
Johnson, M. [1 ]
Koss, D. [1 ]
Thomas, A. J. [1 ]
Attems, J. [1 ]
机构
[1] Newcastle Univ, Translat & Clin Res Inst, Campus Ageing & Vital, Newcastle Upon Tyne NE4 5PL, Tyne & Wear, England
基金
英国医学研究理事会;
关键词
Alzheimer's disease; LATE-NC; TDP-43; tau pathology; FRONTOTEMPORAL LOBAR DEGENERATION; BINDING PROTEIN 43; HIPPOCAMPAL SCLEROSIS; NEUROPATHOLOGIC ASSESSMENT; TDP-43; PATHOLOGY; COGNITIVE IMPAIRMENT; NATIONAL INSTITUTE; DEMENTIA; GUIDELINES; OLD;
D O I
10.1111/nan.12664
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Aims Limbic-predominant age-related TDP-43 encephalopathy neuropathological change (LATE-NC) is present in approximately 50% of Alzheimer's disease (AD) cases and is associated with accelerated cognitive decline. Studies indicate a potential synergistic relationship between LATE-NC and hyperphosphorylated tau. It is unknown if LATE-NC is an independent driver of cognitive impairment or exerts its influence through synergistic relationships with tau. This cliniconeuropathological study investigated the impact of LATE-NC on quantified measures of AD-associated pathology and its impact on clinical measures. Methods A total of 61 AD cases underwent neuropathological assessment for LATE-NC and quantitative assessment [area covered by immunoreactivity (IR)] for early conformational tau (MC-1), late-stage hyperphosphorylated tau (AT8) and amyloid-beta in the amygdala and five neocortical regions. Clinical measures included age of disease onset, final Mini-Mental State Examination (MMSE) score and rate of cognitive decline. Results LATE-NC was present in 41 AD cases (AD/LATE-NC; 67.2%). No significant differences in MC-1-IR, AT8-IR or 4G8-IR were observed in any region between AD/LATE-NC and AD without LATE-NC, indicating no accelerated aggregation or hyperphosphorylation of tau proteins in the AD/LATE-NC cases. Final MMSE was significantly lower in AD/LATE-NC cases and was significantly associated with LATE-NC score even when controlled for the presence of both MC-1-IR and AT8-IR (P = 0.009). Conclusion The presence of LATE-NC in AD is not associated with an increase in the burden of early or late tau or A beta pathology. LATE-NC is associated with a lower final MMSE score independent of tau pathology.
引用
收藏
页码:722 / 734
页数:13
相关论文
共 50 条
  • [1] LATE-NC exacerbates tau pathology and seeding potential in Alzheimer's disease
    Tome, S.
    Tsaka, G.
    Ronisz, A.
    Ospitalieri, S.
    Gawor, K.
    Otto, M.
    Von Arnim, C. A. F.
    Van Damme, P.
    Van den Bosch, L.
    Vandenberghe, R.
    Schymkowitz, J.
    Rousseau, F.
    Thal, D. R.
    BRAIN PATHOLOGY, 2023, 33
  • [2] The impact of concomitant LATE-NC on hyperphosphorylated-τ pathology and cognitive decline in Alzheimer's disease
    McAleese, K. E.
    Walker, L.
    Erskine, D.
    Attems, J.
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2020, 46 : 37 - 37
  • [3] LATE-NC in Alzheimer's disease: Molecular aspects and synergies
    Tome, Sandra O.
    Gawor, Klara
    Thal, Dietmar Rudolf
    BRAIN PATHOLOGY, 2024, 34 (04)
  • [4] Amyloid-β and Tau at the Crossroads of Alzheimer's Disease
    Gallardo, Gilbert
    Holtzman, David M.
    TAU BIOLOGY, 2019, 1184 : 187 - 203
  • [5] Pyroglutamylated amyloid-β is associated with hyperphosphorylated tau and severity of Alzheimer's disease
    Mandler, Markus
    Walker, Lauren
    Santic, Radmila
    Hanson, Peter
    Upadhaya, Ajeet Rijal
    Colloby, Sean J.
    Morris, Christopher M.
    Thal, Dietmar R.
    Thomas, Alan J.
    Schneeberger, Achim
    Attems, Johannes
    ACTA NEUROPATHOLOGICA, 2014, 128 (01) : 67 - 79
  • [6] Pyroglutamylated amyloid-β is associated with hyperphosphorylated tau and severity of Alzheimer’s disease
    Markus Mandler
    Lauren Walker
    Radmila Santic
    Peter Hanson
    Ajeet Rijal Upadhaya
    Sean J. Colloby
    Christopher M. Morris
    Dietmar R. Thal
    Alan J. Thomas
    Achim Schneeberger
    Johannes Attems
    Acta Neuropathologica, 2014, 128 : 67 - 79
  • [7] Is diabetes associated with increased pathological burden in Alzheimer's disease?
    Sadrolashrafi, Kaviyon
    Craft, Suzanne
    Decourt, Boris
    Adem, Abdu
    Wilson, Jeffrey R.
    Miller, Justin
    Sabbagh, Marwan N.
    ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING, 2021, 13 (01)
  • [8] Untangling Amyloid-β, Tau, and Metals in Alzheimer's Disease
    Savelieff, MG
    Lee, S
    Liu, YZ
    Lim, MH
    ACS CHEMICAL BIOLOGY, 2013, 8 (05) : 856 - 865
  • [9] The Dichotomy of Alzheimer's Disease Pathology: Amyloid-β and Tau
    Ashford, J. Wesson
    JOURNAL OF ALZHEIMERS DISEASE, 2019, 68 (01) : 77 - 83
  • [10] Synergy between amyloid-β and tau in Alzheimer's disease
    Busche, Marc Aurel
    Hyman, Bradley T.
    NATURE NEUROSCIENCE, 2020, 23 (10) : 1183 - 1193